Therapeutic serum level for adalimumab in rheumatoid arthritis: explorative analyses of data from a randomised phase III trial
Authors:
- Johanna Elin GehinJGJohanna Elin Gehin
- Rolf Anton KlaasenRKRolf Anton Klaasen
- Eirik Klami KristianslundEKEirik Klami Kristianslund
- Ingrid JyssumIJIngrid Jyssum
- Joseph SextonJSJoseph Sexton
- David John WarrenDWDavid John Warren
- Daniel AletahaDADaniel Aletaha
- Espen Andre HaavardsholmEHEspen Andre Haavardsholm
- Silje Watterdal SyversenSSSilje Watterdal Syversen
- Guro Løvik GollGGGuro Løvik Goll
- Nils BolstadNBNils Bolstad
Open Access
Abstract
Objectives The objectives of this study are to identify a therapeutic serum level for adalimumab associated with remission and low disease activity in patients with rheumatoid arthritis. Methods Associations between serum adalimumab trough levels and disease activity were examined using longitudinal data from a 48-week randomised phase III trial including patients with tumour necrosis factor inhibitor-naïve rheumatoid arthritis with active disease starting adalimumab treatment. Disease activity was classified according to 28-joint Disease Activity Score (DAS28)-erythrocyte sedimentation rate and C reactive protein (CRP) levels. Results Adalimumab trough levels were recorded longitudinally for 336, 330 and 302 patients at weeks 12, 24 and 48, respectively. All patients received concomitant methotrexate. Median adalimumab trough levels were 6.4 mg/L (IQR 3.4–9.5) at week 12, 7.5 mg/L (IQR 3.5–10.9) at week 24 and 7.6 mg/L (IQR 3.6–12.0) at week 48. In serial serum samples from weeks 12, 24 and 48, trough levels ≥3.9 mg/L were associated with DAS28 remission (OR 3.88 (95% CI 1.80, 8.38), pConclusion Adalimumab trough levels above 4.0 mg/L were associated with remission/low disease activity throughout the first year of adalimumab therapy and can be considered a lower target level for therapeutic drug monitoring of adalimumab therapy.Keywords
Funding Information
- European Union (101095052)
This publication has 26 references indexed in Scilit:
- The impact of a disease flare during tapering of DMARDs on the lives of rheumatoid arthritis patientsSeminars in Arthritis and Rheumatism, 2020
- Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trialAnnals of the Rheumatic Diseases, 2018
- Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO TrialClinical Therapeutics, 2018
- Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic ReviewBioDrugs, 2017
- Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-AnalysisBioDrugs, 2015
- Key findings towards optimising adalimumab treatment: the concentration–effect curveAnnals of the Rheumatic Diseases, 2015
- Long-Term Drug Survival of TNF Inhibitor Therapy in RA Patients: A Systematic Review of European National Drug RegistersInternational Journal of Rheumatology, 2013
- Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent mannerAnnals of the Rheumatic Diseases, 2012
- Validation of rheumatoid arthritis improvement criteria that include simplified joint counts1998
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995